Using DMTs beyond patients with active MS

Xavier Montalban, MD, PhD, MBA, Vall d’Hebron University Hospital, Barcelona, Spain, discusses administering disease modifying therapies (DMTs) for patients who have multiple sclerosis (MS) and may not have MRI activity. Current therapies such as siponimod for secondary progressive MS (SPMS) and ocrelizumab for primary progressive MS (PPMS) are currently only prescribed for patients with progressive or relapsed disease. However, relapses can be difficult to identify and can be missed, especially when monitoring can be sporadic. This interview was conducted during the 2022 World Congress on Controversies in Neurology (CONy) meeting.